ALGEN
DEAD

Serial Number

99443984

Owner

Algen Biotechnologies, Inc.

Attorney

Aaron D. Hendelman

Filing Date

Oct 15, 2025

Add to watchlist:

No watchlists yet
View on USPTO

ALGEN Trademark

Serial Number: 99443984

ALGEN is a trademark filed by Algen Biotechnologies, Inc. on October 15, 2025. The trademark is classified under Class 9 (Computers & Electronics), Class 42 (Computer & Scientific). The application is currently no longer active.

Owner Contact Info

Algen Biotechnologies, Inc. (3 trademarks)

665 3rd Street Suite #280
San Francisco, CA 94107

Entity Type: 03

Trademark Details

Filing Date

October 15, 2025

Registration Date

Not Registered

Goods & Services

Development of software, artificial intelligence, CRISPR technology, therapeutics, and pharmaceuticals; development of software, artificial intelligence, CRISPR technology, therapeutics, and pharmaceuticals for managing therapeutic discovery activities related to gene networking; research and development in the field of drug discovery; drug discovery services; research and development of therapeutics to treat diseases utilizing a proprietary drug discovery platform; design and development of computer software that utilizes artificial intelligence and CRISPR technology; providing temporary use of non-downloadable computer software using artificial intelligence and CRISPR technology for reverse engineering disease trajectory; scientific and technological services, namely, computer aided scientific analysis in the field of artificial intelligence, CRISPR technology, machine learning, deep learning, science, chemistry, physics, and biology; computer modeling services; providing temporary use of non-downloadable computer software using artificial intelligence and CRISPR technology for analyzing and identifying dynamic gene expression changes and disease-driving RNA pathways; providing temporary use of non-downloadable computer software using artificial intelligence and CRISPR technology for predicting gene expression changes during disease progression; providing temporary use of non-downloadable computer software using artificial intelligence and CRISPR technology for precise gene editing and modulation; providing temporary use of non-downloadable computer software using artificial intelligence and CRISPR technology for discovering gene targets for further evaluation and development; scientific research and product development in the field of genetics and drug discovery; scientific research, namely, identification, isolation, functional analysis, sequencing and mapping of genes; research and development in the field of biotechnology and gene networking technology for use in therapeutic discovery and development; scientific research and technological research in the fields of gene discovery, gene network informatics, and drug discovery; managing therapeutic discovery activities related to gene networking, namely, screening and prioritizing therapeutic agents for further evaluation and development, discovering novel biomarkers, validating biomarker strategies, gathering insights for patient selection and stratification for therapeutic treatment, and generating and storing therapeutic insights about the role a particular gene plays in a given disease and about the mechanism of action and therapeutic index of particular therapeutic agents

Downloadable software using artificial intelligence and CRISPR technology for reverse engineering disease trajectory; downloadable software using artificial intelligence and CRISPR technology for analyzing and identifying dynamic gene expression changes and disease-driving RNA pathways; downloadable software using artificial intelligence and CRISPR technology for predicting gene expression changes during disease progression; downloadable software using artificial intelligence and CRISPR technology for precise gene editing and modulation; downloadable software using artificial intelligence and CRISPR technology for discovering gene targets for further evaluation and development; downloadable software using artificial intelligence and CRISPR technology for use in drug discovery; downloadable software using artificial intelligence and CRISPR technology for use in the identification, isolation, functional analysis, sequencing and mapping of genes; downloadable software using artificial intelligence and CRISPR technology for managing therapeutic discovery activities related to gene networking; downloadable software using artificial intelligence and CRISPR technology for identification, isolation, functional analysis, sequencing and mapping of genes

Filing History

ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
May 26, 2026 MAB2
ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
May 26, 2026 ABN2
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jan 29, 2026 GNRN
NON-FINAL ACTION E-MAILED
Jan 29, 2026 GNRT
NON-FINAL ACTION WRITTEN
Jan 29, 2026 CNRT
ASSIGNED TO EXAMINER
Jan 14, 2026 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jan 14, 2026 NWOS
APPLICATION FILING RECEIPT MAILED
Oct 15, 2025 MAFR
NEW APPLICATION ENTERED
Oct 15, 2025 NWAP